What is Otonomy?
Otonomy is a pioneering biopharmaceutical firm dedicated to the development of innovative therapeutics for neurotology. The company distinguishes itself through the application of advanced drug delivery technology designed for the ear, enabling sustained drug exposure via a single local administration. This proprietary approach, supported by a comprehensive patent estate, targets significant unmet medical needs, specifically within the domains of hearing loss and tinnitus. By focusing on localized treatment, Otonomy aims to improve patient outcomes while minimizing systemic side effects, positioning itself as a leader in the specialized field of otic medicine.
How much funding has Otonomy raised?
Otonomy has raised a total of $448.4M across 7 funding rounds:
Series A
$10M
Series B
$38.5M
Series C
$45.9M
Series D
$49M
Stock Offering
$104M
Stock Offering
$86M
Stock Offering
$115M
Series A (2010): $10M with participation from Avalon Ventures
Series B (2010): $38.5M led by Domain Associates, TPG Biotech, Novo Ventures, RiverVest Venture Partners, and Avalon Ventures
Series C (2013): $45.9M supported by Domain Associates, OrbiMed, TPG Biotech, APERTURE Venture Partners, Avalon Ventures, Novo Ventures, RiverVest Venture Partners, and Osage University Partners
Series D (2014): $49M featuring Ally Bridge Group, Osage University Partners, APERTURE Venture Partners, Jennison Associates, Avalon Ventures, Novo Ventures, RiverVest Venture Partners, Domain Associates, OrbiMed, TPG Biotech, Federated Kaufmann Funds, Perceptive Advisors, and Clough Capital Partners
Stock Issuance/Offering (2014): $104M backed by Undisclosed
Stock Issuance/Offering (2015): $86M with participation from Undisclosed
Stock Issuance/Offering (2016): $115M led by Undisclosed
Key Investors in Otonomy
Domain Associates
DomainVC is an investment advisory firm established in 1985, specializing in biotech investments with a track record of 90 IPOs and 110 M&A events.
TPG Biotech
TPG is a global alternative asset management firm founded in 1992 that oversees a diversified portfolio across multiple industries and investment stages.
Avalon Ventures
Avalon Ventures is a venture capital firm with over 30 years of experience focusing on seed and early-stage companies, particularly in the life sciences and information technology sectors.
What's next for Otonomy?
With the infusion of capital from its latest financing round, Otonomy is well-positioned to accelerate its clinical development programs and expand its market reach. The strategic focus remains on scaling its pipeline and refining its drug delivery platform to address broader indications within the neurotology space. As the company matures, it will likely prioritize regulatory milestones and commercial readiness, leveraging the deep industry expertise of its long-term investment partners to navigate the competitive landscape of the biopharmaceutical sector.
See full Otonomy company page
